Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All drugs

Rivoceranib

Stage Phase 2

Sponsor Elevar Therapeutics

Route oral

Modality small molecule

Class VEGFR2 TKI

Mechanism VEGFR2 inhibitor

Target VEGFR2 (KDR)

Sources

registry, as of 2026-11-07

https://pubmed.ncbi.nlm.nih.gov/37643133/

A Phase II Trial of Rivoceranib for Recurrent or Metastatic Adenoid Cystic Carcinoma, Clin Cancer Res, 11.14.2023, PMID 37643133 (publication abstract; opened 2026-10-27) and registry results NCT04119453 (posted 07.30.2026): 80 enrolled, 72 evaluable, 700 mg once daily; ORR 15.3% investigator and 9.7% independent review; median DoR 14.9 and 7.2 months; median PFS 9.0 months; grade 3 or higher TRAEs 70.0% (hypertension 42.5%); dose modifications 85.0%; discontinued for toxicity 20.0% (16 patients); four grade 5 events. Registry (all 80): ORR 13.8% (95% CI 7.1 to 23.3) investigator, 8.8% independent review; 12-month PFS 37.3%; serious AEs 32 of 80.

Brief source A24

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT04119453

A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Rivoceranib Phase 2

Registry NCT04119453

Phase Phase 2

Status Terminated

Enrollment 80

Start 2020-01-22

Primary completion 2023-06-28

Study completion 2023-06-28

Rivoceranib 700 mg

Dose 700 mg

Regimen once daily

Population R/M ACC (n = 80; 72 evaluable)

Estimand Single arm

objective response rate (investigator): 15.3%, primary analysis

objective response rate (independent review): 9.7%, primary analysis

median progression-free survival: 9 months, primary analysis

median duration of response (investigator): 14.9 months, primary analysis

grade 3 or higher treatment-related adverse events: 70%, primary analysis

discontinued for toxicity: 20%, primary analysis